Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 4, 2021

View Archived Issues

China's NMPA accepts Kintor's IND for topical AR degrader GT-20029

FDA authorizes initiation of pivotal phase III study of NE-3107 in AD

A bivalent measles-based COVID-19 vaccine shows antiviral efficacy in vivo and Th1-biased responses

Multivalent nanobodies potently neutralize SARS-CoV-2 and prevent mutational escape

Positive topline data from phase II study of Allocetra in severe and critical COVID-19

Crinetics initiates phase I study of CRN-04777

Preliminary phase I data show safety and immunogenicity of VXA-CoV2-1 oral tablet vaccine

New cannabinoid CB1 and CB2 receptor ligands identified at Canopy Growth Corp.

Cybrexa 3 patents peptide conjugates of microtubule-targeting agents

Novartis discovers AKR1C3-dependent GTPase KRAS inhibitors

California Institute of Technology, Rockefeller University describe anti-HIV vaccine antibodies

Phase Ib data show lack of objective response for CMP-001 plus atezolizumab in NSCLC

RCC-33 reduces tumor volume in mice inoculated with colorectal cancer cells

ABTL-0812 plus paclitaxel and carboplatin result in increased efficacy in NSCLC

ViaCyte begins phase II study of VC01-103 in type 1 diabetes

JADE family of markers has prognostic value in NSCLC

New dengue virus inhibitor shows preclinical promise

CRY1 protein activators allow circadian clock manipulation with light

Roche discloses new monoglyceride lipase inhibitors

Erlotinib plus anlotinib shows promise in EGFR-mutated NSCLC

FDA grants accelerated approval to Tepmetko for metastatic NSCLC with METex14 skipping alterations

Daiichi Sankyo initiates phase II study of patritumab deruxtecan in EGFR-mutated NSCLC

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 10, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 9, 2026
Skape Bio unlocks GPCR targets with de novo-designed miniproteins
BioWorld
Modulating G protein-coupled receptors (GPCRs) is one of the major challenges in biomedicine. These are flexible proteins with small, deep binding pockets. The...
Antares Therapeutics divulges new CDK2/cyclin E1 inhibitors
BioWorld Science
Antares Therapeutics Inc. has reported new CDK2/cyclin E1 inhibitors potentially useful for the treatment of cancer.
Empire Discovery Institute, Univ. of Rochester identify IRAK inhibitors
BioWorld Science
Empire Discovery Institute and the University of Rochester have discovered new interleukin-1 receptor-associated kinase 1 (IRAK-1) and/or IRAK-4 inhibitors...